| Title |
Long-acting beta2-agonists for chronic obstructive pulmonary disease
|
|---|---|
| Published in |
Cochrane database of systematic reviews, October 2013
|
| DOI | 10.1002/14651858.cd010177.pub2 |
| Pubmed ID | |
| Authors |
Kayleigh M Kew, Chris Mavergames, Julia AE Walters |
| Abstract |
Chronic obstructive pulmonary disease (COPD) is a respiratory disease that causes progressive symptoms of breathlessness, cough and mucus build-up. It is the fourth or fifth most common cause of death worldwide and is associated with significant healthcare costs.Inhaled long-acting beta2-agonists (LABAs) are widely prescribed to manage the symptoms of COPD when short-acting agents alone are no longer sufficient. Twice-daily treatment with an inhaled LABA is aimed at relieving symptoms, improving exercise tolerance and quality of life, slowing decline and even improving lung function and preventing and treating exacerbations. |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 4 | 27% |
| Canada | 1 | 7% |
| Ecuador | 1 | 7% |
| United Kingdom | 1 | 7% |
| France | 1 | 7% |
| Germany | 1 | 7% |
| Unknown | 6 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 87% |
| Science communicators (journalists, bloggers, editors) | 1 | 7% |
| Practitioners (doctors, other healthcare professionals) | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 298 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | <1% |
| United States | 1 | <1% |
| Netherlands | 1 | <1% |
| South Africa | 1 | <1% |
| Unknown | 293 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 45 | 15% |
| Student > Bachelor | 34 | 11% |
| Student > Ph. D. Student | 33 | 11% |
| Researcher | 30 | 10% |
| Other | 24 | 8% |
| Other | 56 | 19% |
| Unknown | 76 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 123 | 41% |
| Nursing and Health Professions | 24 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 15 | 5% |
| Psychology | 14 | 5% |
| Social Sciences | 12 | 4% |
| Other | 27 | 9% |
| Unknown | 83 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 September 2022.
All research outputs
#1,008,683
of 24,417,958 outputs
Outputs from Cochrane database of systematic reviews
#2,126
of 12,911 outputs
Outputs of similar age
#9,169
of 216,138 outputs
Outputs of similar age from Cochrane database of systematic reviews
#42
of 208 outputs
Altmetric has tracked 24,417,958 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,911 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 34.5. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 216,138 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 208 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.